B-196 Comprehensive clinical validation of the Immunoglobulin Isotypes (GAM) assay for the EXENT® Analyzer assay in monoclonal gammopathies
Abstract
Mass spectrometry is an emerging alternative to electrophoretic methods for routine analysis of serum M-proteins. The Immunoglobulin Isotypes (GAM) assay for the EXENT® Analyzer (henceforth referred to as EXENT; The Binding Site, part of Thermo Fisher Scientific) supports detection and isotyping of intact monoclonal immunoglobulins based on their unique mass-to-charge signatures. When used in conjunction with the Optilite IgG, IgA, and IgM assays, the workflow provides semi-quantitative assessment of intact monoclonal immunoglobulins. We assessed the clinical performance of EXENT as an aid in the diagnostic workup of multiple myeloma (MM) and related monoclonal gammopathies, and evaluated its agreement with serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE). Residual serum samples were tested with EXENT at three sites. The clinical performance evaluation included patients with clinically confirmed monoclonal gammopathies, disease controls in whom monoclonal gammopathy had been ruled out, apparently healthy subjects used to establish isotype-specific cut-offs, and a cross-reactivity cohort. For the primary analyses, patients with light chain-only and IgD monoclonal gammopathies were excluded. A positive EXENT result was defined as detection of an intact IgG, or IgM M-protein at or above the isotype-specific cut-off values (IgG 0.359 g/L, IgA 0.325 g/L, IgM 0.197 g/L); otherwise, results were classified as negative. Diagnostic sensitivity and specificity (with 95% confidence intervals) were calculated versus clinical diagnosis. For samples with quantifiable M-protein by SPE, concentration agreement was assessed using Passing-Bablok regression, and isotype agreement was assessed versus IFE (excluding biclonal samples per protocol). In the intended use monoclonal gammopathy cohort (n=688), diagnostic sensitivity was 94.3% (95% CI 92.3-95.8), including 92.1% for monoclonal gammopathy of undetermined significance (n=227), 98.6% for smoldering MM (n=140), 94.4% for MM (n=180), 98.4% for Waldenström’s macroglobulinemia (n=64), and 89.6% for AL amyloidosis (n=77). Diagnostic specificity in disease controls (n=655) was 87.8% (95% CI 85.1-90.1). Among apparently healthy subjects (n=364), 6.3% had at least one intact immunoglobulin M-protein at or above the cut-off. Positivity by EXENT was greater than or equivalent to SPE overall (94.3% vs 93.5%), with higher positivity in AL amyloidosis (89.6% vs 80.5%). On SPE-positive samples, isotype concordance with IFE was 95.3% overall, with agreement of 97.1% for IgG, 96.0% for IgA, and 89.2% for IgM. Quantitative comparison versus SPE (571 paired data points) demonstrated Passing-Bablok slopes of 1.13 overall, 1.10 for IgG, 0.91 for IgA, and 1.54 for IgM, consistent with a positive bias for IgM quantification attributable to known method differences in total IgM measurement versus densitometry. In a cross-reactivity cohort (n=144), EXENT positivity was 29.9% in leukemia/lymphoma (primarily B-cell lineage malignancies) and 8.5% in infectious etiologies. The Immunoglobulin Isotypes (GAM) assay on the EXENT Analyzer demonstrated high diagnostic sensitivity for intact IgG, and IgM monoclonal gammopathies, and good specificity. The assay showed strong agreement with IFE for isotype assignment and acceptable quantitative agreement with SPE for IgG and IgA. IgM quantification showed a predictable positive bias and slightly lower isotype concordance, consistent with method-specific differences, and should be interpreted accordingly.